A5082031977- Retinal Diseases and Treatments
- Retinal Development and Disorders
- Retinal and Optic Conditions
- Retinal Imaging and Analysis
- Glaucoma and retinal disorders
- Ophthalmology and Visual Impairment Studies
- Ocular Diseases and Behçet’s Syndrome
- Mitochondrial Function and Pathology
- Systemic Lupus Erythematosus Research
- Ocular Disorders and Treatments
- Genomics and Rare Diseases
- Drug-Induced Ocular Toxicity
- Photoreceptor and optogenetics research
- Retinal and Macular Surgery
- RNA regulation and disease
- ATP Synthase and ATPases Research
- Sleep and related disorders
- Ocular Oncology and Treatments
- Cerebral Venous Sinus Thrombosis
- Cellular transport and secretion
- Ubiquitin and proteasome pathways
- Intraocular Surgery and Lenses
- Retinoids in leukemia and cellular processes
- Ocular and Laser Science Research
- Genomic variations and chromosomal abnormalities
University of Oxford
2016-2025
Neuroscience Institute
2025
John Radcliffe Hospital
2015-2024
Oxford University Hospitals NHS Trust
2015-2024
Nuffield Orthopaedic Centre
2012-2024
Towson University
2024
Oxford Health NHS Foundation Trust
2023-2024
Queen Alexandra Hospital
2022-2023
National Health Service
2013-2022
Moorfields Eye Hospital NHS Foundation Trust
1999-2022
OBJECTIVE--To examine whether the observed excess of childhood leukaemia and lymphoma near Sellafield nuclear plant is associated with established risk factors or related to plant. DESIGN--A case-control study. SETTING--West Cumbria health district. SUBJECTS--52 Cases leukaemia, 22 non-Hodgkin9s lymphoma, 23 Hodgkin9s disease occurring in people born area diagnosed there 1950-85 under age 25 1001 controls matched for sex date birth taken from same registers as cases. MAIN OUTCOME...
Bevacizumab has been suggested to have similar effectiveness ranibizumab for treatment of neovascular age-related macular degeneration. The Inhibition VEGF in Age-related choroidal Neovascularisation (IVAN) trial was designed compare these drugs and different regimens. Here, we report the findings at prespecified 2-year timepoint.In a multicentre, 2×2 factorial, non-inferiority randomised trial, enrolled adults aged least 50 years with active, previously untreated degeneration best corrected...
To compare the anatomic and functional efficacy safety of half-dose photodynamic therapy (PDT) versus high-density subthreshold micropulse laser (HSML) treatment in patients with chronic central serous chorioretinopathy (cCSC).
In chronic central serous chorioretinopathy (CSCR), fluid accumulates in the subretinal space. CSCR is a common visually disabling condition that develops individuals up to 60 years of age, and there no definitive treatment. Previous research suggests mineralocorticoid receptor antagonist, eplerenone, effective for treating CSCR; however, this drug not licensed treatment patients with CSCR. We aimed evaluate whether eplerenone was superior placebo terms improving visual acuity CSCR.This...
Central serous chorioretinopathy (CSC) is a relatively common disease that causes vision loss due to macular subretinal fluid leakage and often associated with reduced vision-related quality of life. In CSC, the through defects in retinal pigment epithelial layer's outer blood-retina barrier appears occur secondary choroidal abnormalities dysfunction. The treatment CSC currently subject controversy, although recent data obtained from several large randomized controlled trials provide wealth...
Chronic central serous chorioretinopathy: long-term follow-up and vision-related quality of life Myrte B Breukink,1,* Alexander JM Dingemans,1,* Anneke I den Hollander,1,2 Jan EE Keunen,1 Robert E MacLaren,3,4 Sascha Fauser,5 Giuseppe Querques,6 Carel Hoyng,1 Susan M Downes,3,4 Camiel JF Boon1,7 1Department Ophthalmology, 2Department Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands; 3Oxford Eye Hospital, Oxford Hospitals NHS Trust, 4Nuffield Laboratory...
Retinitis pigmentosa (RP) is the most frequent form of inherited retinal dystrophy. RP genetically heterogeneous and genes identified to date encode proteins involved in a wide range functional pathways, including photoreceptor development, phototransduction, retinoid cycle, cilia, outer segment development. Here we report identification biallelic mutations Receptor Expression Enhancer Protein 6 (REEP6) seven individuals with autosomal-recessive from five unrelated families. REEP6 member...
Independent navigation for blind individuals can be extremely difficult due to the inability recognise and avoid obstacles. Assistive techniques such as white canes, guide dogs, sensory substitution provide a degree of situational awareness by relying on touch or hearing but yet there are no that attempt make use any residual vision individual is likely retain. Residual restricted orientation light source, hence information presented wearable display would have limited unambiguous. For...
The cause of autosomal-dominant retinitis pigmentosa (adRP), which leads to loss vision and blindness, was investigated in families lacking a molecular diagnosis. A refined locus for adRP on Chr17q22 (RP17) delineated through genotyping genome sequencing, leading the identification structural variants (SVs) that segregate with disease. Eight different complex SVs were characterized 22 adRP-affected >300 affected individuals. All RP17 had breakpoints within genomic region spanning YPEL2...
Records on 1068 children who were born to mothers resident in Seascale Civil Parish during 1950-83 studied. There was a large degree of mobility among the families, and nearly half did not subsequently attend main local school. Use National Health Service Central Register, however, enabled us follow up children9s records regardless place residence. The excess leukaemia first supported from analysis geographical areas is confirmed. five deaths identified 30 June 1986 compared with 0.53...
Background Bevacizumab (Avastin ® , Roche), which is used in cancer therapy, the ‘parent’ molecule from ranibizumab (Lucentis Novartis) was derived for treatment of neovascular age-related macular degeneration (nAMD). There were reports literature on effectiveness bevacizumab treating nAMD, but no trials. The cost per dose about 5–10% that ranibizumab. This trial a head-to-head comparison these two drugs. Objective To compare clinical and cost-effectiveness bevacizumab, regimens, nAMD....
To investigate mitophagy in 5 patients with severe dominantly inherited optic atrophy (DOA), caused by depletion of OPA1 (a protein that is essential for mitochondrial fusion), compared healthy controls.Patients DOA (DOA plus) had peripheral neuropathy, cognitive regression, and epilepsy addition to loss vision. We quantified dermal fibroblasts, using 2 high throughput imaging systems, visualizing colocalization fragments engulfing autophagosomes.Fibroblasts from 3 biallelic OPA1(-/-)...